Jefferies highlights implications of weight loss drug GLP-1 on re/insurance sector
Reinsurance News - Sep 29, 2023
In Jefferies’ recent “Assessing the Wider Implications of a Slimmer Society” report, the firm’s analysts underlined some of the key ways in which Glucagon-like peptide-1 receptor agonists (or GLP-1s) could affect the re/insurance sector. According to the analysts, GLP-1s were...
Recommended Articles
Posted: Apr 16, 2026
Capgemini Research Institute, the research division of the Capgemini, has published the report Physi...
Posted: Apr 16, 2026
Beazley, a large specialist insurer, has announced plans to establish a new Marine War insurance con...
Posted: Apr 16, 2026
John Doyle, President and Chief Executive Officer (CEO) of global insurance and reinsurance broking...